e-ISSN: Pending
Negative / Null Result ReportOpen accessEnvironmental Science· cited by 60

A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain

Neil A. Hagen; Bernard Lapointe; May Ong-Lam; Benoit Dubuc; David Walde; Bruno Gagnon; Robin Love; Ravi Kumar Goel · 2011 · Current Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Cancer pain is highly prevalent, and existing treatments are often insufficient to provide adequate relief. OBJECTIVES: We assessed the long-term safety and efficacy of subcutaneous tetrodotoxin treatment in reducing the intensity of chronic cancer-related pain. METHODS: In this multicentre open-label longitudinal trial, 30 μg tetrodotoxin was administered subcutaneously twice daily for 4 days in a heterogeneous cohort of patients with persistent pain despite opioids and other analgesics. "Responder" was defined as a mean reduction of 30% or more in pain intensity from baseline; an

Abstract by Neil A. Hagen; Bernard Lapointe; May Ong-Lam; Benoit Dubuc; David Walde; Bruno Gagnon; Robin Love; Ravi Kumar Goel, Current Oncology (2011) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.3747/co.v18i3.732